Evidence map›Paper›PMID 42622492›Full record

ReviewArchiv der Pharmazie2026

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Xin-Ke Guo, Kadalipura P Rakesh, Sahana Raju, Kothanahally S Sharath Kumar, Hua-Li Qin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin-Ke GuoSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, People's Republic of China.
Kadalipura P RakeshSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, People's Republic of China.ORCID https://orcid.org/0000-0001-9317-8462
Sahana RajuDepartment of Physics, GSSS Institute of Engineering and Technology for Women, Metagalli, Mysuru, Visvesvaraya Technological University, Belagavi, Mysuru, Karnataka, India.
Kothanahally S Sharath KumarDepartment of Studies in Chemistry, Manasagangotri, University of Mysore, Mysuru, India.ORCID https://orcid.org/0000-0003-4378-9833
Hua-Li QinSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, People's Republic of China.

Funding

the National Natural Science Foundation of China 22578341the Wuhan University of Technology for their support
6 · The paper itself

Abstract

Incorporating current structural and biochemical discoveries, this paper examines how B-RAF inhibitors control B-RAF, including their clinical efficacy, side effects, and important medicinal chemistry characteristics. It investigates the molecular insights that may direct the creation of more potent RAF inhibitors that can target different oncogenic B-RAF conformations. We have discussed the advantages and disadvantages of structurally varied next-generation RAF inhibitors that are presently undergoing preclinical and clinical trials. A few of these drug candidates have started clinical trials with promising outcomes. This review also covers the structure-activity relationship of promising bioactive B-RAF compounds, highlights advancements in the discovery and development of B-RAF inhibitors, and attempts to assist future drug discovery initiatives.

Indexed as

Antineoplastic AgentsDrug DiscoveryNeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAnimalsHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF inhibitordrug discoverySAR

Identifiers

PMID42622492
PMCPMC13492227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.